1Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model[J]. QJM, 2003, 96(4): 281-288.
2Garber AJ, Abrahamson MJ, Barzilay JI, et aI. American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Alogrithm 2013 Consensus Statement[J]. Endocr Pratt, 2013, 19(3): 536-557.
3American Diabetes Association. Standards of medical care in diabetes- 2014[J]. Diabetes Care, 2014, 37(Suppl 1): S14-80.
4Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J]. Diabetologia, 2012, 55(6): 1577-1596.
5International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes[J]. Diabetes Res Clin Pract, 2014, 104(1): 1-52.
7Heise T, Nosek L, Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes[J]. Diabetes, 2004, 53(6): 1614-1620.
8Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues(insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes[J]. Diabetes Obes Metab, 2007, 9(3): 290-299.
9Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal insulin analogues based on isoglycaemic clamp studies[J]. Diabetes Obes Metab, 2007, 9(5): 648- 659.
10Rosenstock J, Davies M, Home PD, et aI. A randomised, 52-week, treat- to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes[J]. Diabetologia, 2008, 51 (3): 408-416.
1Xu Y,Wang L,He J,et a/.Prevalence and control of dia- betes in Chinese adults[J].JAMA, 20 ! 3,310 (9) : 948-959.
2Chon S,Oh S,Kim SW,et a/.The effect of early insulin therapy on pancreatic beta-cell function and long-term glycemic control in newly diagnosed type 2 diabetic pa- tients[J].Korean J Intern Med, 2010,25 (3) : 273-281.
3Kramer CK,Zinman B, Retnakaran R.Short-term intensive insulin therapy in type 2 diabetes mellitus:a systematic review and meta-analysis[J].Lancet Diabetes Endocrinol, 2013,1(1) :28-34.
4Hendriksen KV,Jensen T, Oturai P,et a/.Effects of insulin detemir and NPH insulin on renal handling of sodium,flu- id retention and weight in type 2 diabetic patients[J].Dia- betologia, 2012,55 ( 1 ) : 46-50.
5Ji L,Li H,Guo X,et glycemic control and a/.Impact of baseline weight change with BMI on metforminmonotherapy in Chinese type 2 diabetes patients:phase IV open-label trial[J].PLoS One, 2013,8 (2) : e57222.
6Garber AJ,Abrahamson MJ,Barzilay JI,et a/.American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus state- ment executive summary[J].Endocr Pract, 2013,19 (3) :536-557.
7Chan JC,Deerochanawong C,Shera AS,et a/.Role of met- formin in the initiation of pharmacotherapy for type 2 di- abetes:an Asian-Pacific perspective[J].Diabetes Res Clin Pract, 2007,75 (3) : 255-266.
8Xu Yu, Wang Limin, He Jiang. Prevalence and control of diabetes in Chinese adults[J]. JAMA,2013,310(9) :948-959.
